Aminoglycoside prescribing and surveillance in cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 6, 2003, Pages 819-823

  Tan, Kelvin H V ^a   Mulheran, Michael ^b   Knox, Alan J ^b   Smyth, Alan R ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Aminoglycoside antibiotics; Cystic fibrosis; Nephrotoxicity; Ototoxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; COLISTIN; GENTAMICIN; IBUPROFEN; NEOMYCIN; TOBRAMYCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HEARING LOSS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PALLOR; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SWEAT GLAND DISEASE; VERTIGO; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; DRUG ADMINISTRATION; DRUG UTILIZATION; HEARING DISORDER; KIDNEY DISEASE; KIDNEY FUNCTION TEST; METABOLISM; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; RISK FACTOR; STANDARD; STATISTICS; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG UTILIZATION; HEARING DISORDERS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PREVALENCE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037445292     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200109-012CC     Document Type: Review

References (47)

1. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis: a preliminary report. Mayo Clin Proc 1945;20:313-318.
2. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997;41:95-100.
3. Mendelman PM, Smith AL, Levy J, Weber A, Ramsay B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765.
4. UK Cystic Fibrosis Trust's Antibiotic Group. Antibiotic Treatment for Cystic Fibrosis 2000. London.
5. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
6. Cystic Fibrosis Foundation. Clinical Practice Guidelines for CF 1997.
7. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987;13:228-253.
8. Hsu M-C, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 1984;3:526-529.
9. Horrevorts AM, Degener JE, Dzoljic-Danilovic G, Michel MF, Kerrebijn KF, Driessen O. Pharmacokinetics of tobramycin in patients with cystic fibrosis: implications for the dosing interval. Chest 1985;88:260-264.
10. Touw DJ, Vinks AA, Jacobs F, Heijerman HG, Bakker W. Creatinine clearance as a predictor of tobramycin elimination rate in adult patients with cystic fibrosis. Ther Drug Monit 1996;18:562-569.
11. Hyatt JM, McKinnon PS, Zimmer G. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995;28:143-160.
12. Touw DJ, Vinks AA, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Clin Pharmacokinet 1998;35:437-459.
13. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Clin Pharmacokinet 1998;34:265-279.
14. McHenry MC, Gavan TL, Gifford RW Jr, Geurkink NA, Van Ommen RA, Town MA, Wagner JG. Gentamicin dosages for renal insufficiency: adjustments based on endogenous creatinine clearance and serum creatinine concentration. Ann Intern Med 1971;74:192-197.
15. Chan RA, Benner JE, Hoeprich PD. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med 1972;76:773-778.
16. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43:1003-1012.
17. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33.
18. Wood PJ, Ioannides-Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, Hoope RE, McLean AJ. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51:369-373.
19. Lerner AM, Cone LA, Jensen W, Reyes MP, Blair DC, Wright GE, Lorber RR. Randomised, controlled trial of the comparative efficacy, auditory toxicity and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1123-1126.
20. Akbar A, Rees JH, Nyamugunduru G, English MW, Spencer DA, Weller PH. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr 1999;88:783-785.
21. Green CG, Doershuk CF, Stern RC. Symptomatic hypomagnesemia in cystic fibrosis. J Pediatr 1985;107:425-428.
22. Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH, Boat TF. Are measurements of urine enzymes useful during aminoglycoside therapy? Pediatr Res 1981;15:1234-1239.
23. Fausti SA, Rappaport BZ, Schechter MA, Frey RH, War TT, Brummett RE. Detection of aminoglycoside ototoxicity by high frequency auditory evaluation: selected case studies. Am J Otolaryngol 1984;5:177-182.
24. McRorie TI, Bosso J, Randolph L. Aminoglycoside ototoxicity in cystic fibrosis. Am J Dis Child 1989;143:1328-1332.
25. Sha SH, Schacht J. Stimulation of free radical formation by aminoglycoside antibiotics. Hear Res 1999;128:112-118.
26. Aran JM. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995;112:133-144.
27. Mulheran M, Degg C, Morgan DW, Stableforth D. The occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high dose aminoglycoside therapy. Antimicrob Agents Chemother 2001;45:2502-2509.
28. Mulheran M, Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol 1998;31:5-9.
29. Lerner S, Matz GJ. Aminoglycoside ototoxicity. Am J Otol 1980;1:169-179.
30. Bragonier R, Brown NM. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998;42:103-106.
31. Morgan DW, Pearman K, Shenoi PM, Stableforth D. Ototoxicity in adult cystic fibrosis: relationship to aminoglycoside blood levels, total dosage, and duration of treatment. Thorax 1988;43:236P.
32. Scott CS, Retsch-Bogart GZ, Henry MM. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol 2001;31:314-316.
33. Begg E, Barclay M. Aminoglycosides - 50 years on. Br J Clin Pharmacol 1995;39:597-603.
34. Stephens SE, Rigden SPA, Price J. Acute renal failure (ARF) in cystic fibrosis patients treated with ceftazidime and gentamicin in combination. Arch Dis Child 2001;84:A10-A68.
35. Bosso JA, Liptak GA, Seilheimer DK, Harrisson GM. Toxicity of colistin in cystic fibrosis patients. DICP 1991;25:1168-1170.
36. Fauconneau B, Favreliere S, Pariat C, Genevrier A, Courtois P, Piriou A, Bouquet S. Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail 1997;19:15-22.
37. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1996;24:796-809.
38. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagon WC. A meta-analysis of extended interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795.
39. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-345.
40. Tan K, Bunn H. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev 2000;4:CD002009.
41. Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax 2001;56:649-655.
42. Bouget P, Fernandez H, Delouis C, Taburet AM. Pharmacokinetics of tobramycin in pregnant women: safety and efficacy of once daily regime. J Clin Pharm Ther 1991;16:167-176.
43. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-226.
44. Ramsey BW. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
45. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-368.
46. Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation. Arch Dis Child 1998;78:540-543.
47. Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg 2002;128:150-155.